Aspen Pharmacare has won the rights to develop, manufacture and commercialize an experimental once-monthly HIV preventive drug in 129 low- and middle-income countries, covering all of Africa
Aspen Pharmacare has won the rights to develop, manufacture and commercialize an experimental once-monthly HIV preventive drug in 129 low- and middle-income countries, covering all of Africa. The drug, Alimatravir, is being developed as a once-monthly oral pre-exposure prophylaxis (PrEP), providing an alternative to daily pill regimens. Aspen said localized production would enhance medical safety across the continent and reduce reliance on imported drugs as new prevention technologies become available.